Pharmacokinetics of Liposomal Amphotericin B in Pleural Fluid-Reference-Cited by-同舟云学术

Pharmacokinetics of Liposomal Amphotericin B in Pleural Fluid

Published:2010-04 Issue:4 Volume:54 Page:1633-1635
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Moriyama Brad¹,Torabi-Parizi Parizad²,Pratt Alexandra K.²,Henning Stacey A.¹,Pennick Gennethel³,Shea Yvonne R.⁴,Roy Chowdhuri Sinchita⁵,Rinaldi Michael G.³,Barrett A. John⁶,Walsh Thomas J.⁵

Affiliation:

1. NIH Clinical Center Pharmacy Department, Bethesda, Maryland

2. Critical Care Medicine Department, Bethesda, Maryland

3. University of Texas Health Science Center, San Antonio, Texas

4. Department of Laboratory Medicine, Bethesda, Maryland

5. National Cancer Institute, Bethesda, Maryland

6. National Heart Lung and Blood Institute, Bethesda, Maryland

Abstract

ABSTRACT We report the penetration of liposomal amphotericin B into the pleural fluid of a patient with pulmonary zygomycosis and empyema. The ratio of area under the concentration-versus-time curve in pleural fluid (AUC pleural fluid ) to that in serum (AUC serum ) for liposomal amphotericin B over 24 h was 9.4%, with pleural fluid concentrations of 2.12 to 4.91 μg/ml. Given the relatively low level of intrapleural penetration of liposomal amphotericin B, chest tube drainage may be warranted for successful treatment of zygomycotic empyema.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01438-09

Reference22 articles.

1. Bindschadler, D. D., and J. E. Bennett. 1969. A pharmacologic guide to the clinical use of amphotericin B. J. Infect. Dis.120:427-436.

2. Chabot, G. G., R. Pazdur, F. A. Valeriote, and L. H. Baker. 1989. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J. Pharm. Sci.78:307-310.

3. Chamilos, G., E. M. Marom, R. E. Lewis, M. S. Lionakis, and D. P. Kontoyiannis. 2005. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin. Infect. Dis.41:60-66.

4. Chamilos, G., M. Luna, R. E. Lewis, G. P. Bodey, R. Chemaly, J. J. Tarrand, A. Safdar, I. I. Raad, and D. P. Kontoyiannis. 2006. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica91:986-989.

5. Cooke, D. T., F. D. Pagani, D. R. Kaul, K. R. Cooke, C. L. Lau, and J. Riddell IV. 2009. Successful treatment of pulmonary zygomycosis in two transplant recipients with liposomal amphotericin B and partial surgical resection followed by posaconazole. Mycoses53:163-167.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disseminated fusariosis after allogenic hematopoietic stem cell transplantation: case report;Infection;2024-08-26

2. Management of Pleural Infection: A Historical Review and Updates;Journal of Respiration;2024-04-26

3. Application and evaluation of topical amphotericin B for the treatment of respiratory fungal infections;BMC Infectious Diseases;2024-04-24

4. The outcomes of thoracoscopic decortication between fungal empyema and bacterial empyema;BMC Infectious Diseases;2023-01-06

5. ERS/ESTS statement on the management of pleural infection in adults;European Respiratory Journal;2022-10-13